ZOSTAVAX
Biological
Merck Sharp & Dohme Corporation
Total Payments
$3.6M
Transactions
23,782
Doctors
13,214
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $5,000 | 1 | 0 |
| 2023 | $257.42 | 11 | 11 |
| 2022 | $105,568 | 2 | 0 |
| 2021 | $759,430 | 4 | 1 |
| 2020 | $441,455 | 8 | 5 |
| 2019 | $739,820 | 102 | 91 |
| 2018 | $525,152 | 2,559 | 2,126 |
| 2017 | $1.0M | 21,095 | 12,390 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 24 | 82.6% |
| Food and Beverage | $315,971 | 23,365 | 8.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $216,316 | 122 | 6.0% |
| Travel and Lodging | $75,516 | 249 | 2.1% |
| Consulting Fee | $9,025 | 6 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $8,450 | 15 | 0.2% |
| Education | $645.21 | 1 | 0.0% |
Payments by Type
Research
$3.0M
24 transactions
General
$625,924
23,758 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Post-licensure Evaluation of the Long-Term Effectiveness of Zostavax | Merck Sharp & Dohme Corporation | $644,477 | 0 |
| Merck Post-Licensure of the Long-Term Effectiveness of Zostavax | Merck Sharp & Dohme Corporation | $550,707 | 0 |
| Zostavax Long-term effectiveness post-lic | Merck Sharp & Dohme Corporation | $375,551 | 0 |
| Post-licensure evaluation of the long-term effectiveness of Zostavax. | Merck Sharp & Dohme Corporation | $356,459 | 0 |
| Post licensure Evaluation of the Long Term Effectiveness of Zostavax | Merck Sharp & Dohme Corporation | $290,367 | 0 |
| Post-licensure Evaluation of the Long Term Effectiveness of Zostavax | Merck Sharp & Dohme Corporation | $201,200 | 0 |
| A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination with Ribavirin RBV in Subjects with chronic Hepatitis C Virus Infection | Merck Sharp & Dohme LLC | $103,415 | 0 |
| VICTOR Study | Merck Sharp & Dohme Corporation | $100,000 | 0 |
| Immune correlates of protection against Herpes Zoster in HIV-infected adults | Merck Sharp & Dohme Corporation | $86,794 | 0 |
| Cutaneous VZV-specific CD4 T-cells long term resident memory T-cells and boosting by Zostavax. | Merck Sharp & Dohme Corporation | $86,395 | 0 |
| Merck Post-Licensure of the Long-Term Effectiveness of ZOSTAVAX | Merck Sharp & Dohme Corporation | $40,868 | 0 |
| Post-Licensure Evalutaion of Long Term Effectiveness of Zostavax | Merck Sharp & Dohme Corporation | $35,742 | 0 |
| Zostavax Long-term effectiveness post-licensure | Merck Sharp & Dohme Corporation | $33,810 | 0 |
| Post-Licensure Evaluation of the Long-Term Effectiveness of Zostavax | Merck Sharp & Dohme Corporation | $33,712 | 0 |
| A pilot study using a randomized design to evaluate the immunologic efficacy and safety of ZOSTAVAX in persons imminently receiving chemotherapy for solid organ tumors. | Merck Sharp & Dohme Corporation | $18,924 | 0 |
| Persistence Of Protection Conferred By Shingrix Against Herpes Zoster in Older Adutls | Merck Sharp & Dohme Corporation | $6,461 | 0 |
| Vitamin D Supplementation and Immune Responses to Zostavax in Older Nursing Home Residents | Merck Sharp & Dohme LLC | $5,000 | 0 |
| Persistence Of Protection Conferred By Shingrix Against Herpes Zoster in Older Adutls | Merck Sharp & Dohme LLC | $2,154 | 0 |
| Assessment of Immunogenicity of Zostavax in Patients with Antibody Deficiency 60 years of age and older | Merck Sharp & Dohme Corporation | $1,879 | 0 |
Top Doctors Receiving Payments for ZOSTAVAX — Page 528
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Family Medicine | Vernon Rockville, CT | $3.73 | 1 |
| , M.D | Family Medicine | Oklahoma City, OK | $3.71 | 1 |
| , MD | Family Medicine | Tyler, TX | $3.70 | 1 |
| , DO | Family Medicine | Milwaukie, OR | $3.69 | 1 |
| , MD | Internal Medicine | Jupiter, FL | $3.69 | 1 |
| , MD | General Practice | Rosemead, CA | $3.65 | 1 |
| , MD | Family Medicine | Thornton, CO | $3.63 | 1 |
| , DO | Family Medicine | Thornton, CO | $3.63 | 1 |
| Robert Meneses | — | Corning, NY | $3.58 | 1 |
| , M.D | Family Medicine | Corning, NY | $3.58 | 1 |
| , M.D | Family Medicine | Benton, AR | $3.39 | 1 |
| , M.D | Family Medicine | Belleville, IL | $3.37 | 1 |
| , MD | Internal Medicine | Nashville, TN | $3.37 | 1 |
| , MD | Family Medicine | Adjuntas, PR | $3.35 | 1 |
| , MD | Internal Medicine | Dunnellon, FL | $3.30 | 1 |
| , D.O | Family Medicine | Fort Worth, TX | $3.27 | 2 |
| , MD | Family Medicine | Augusta, GA | $3.26 | 1 |
| , MD | Family Medicine | Augusta, GA | $3.26 | 1 |
| , MD | Family Medicine | Lexington, SC | $3.19 | 1 |
| , MD | Family Medicine | Wellington, KS | $3.12 | 1 |
| , MD | Family Medicine | Wellington, KS | $3.12 | 1 |
| , MD | Internal Medicine | San Francisco, CA | $3.11 | 1 |
| , MD | Internal Medicine | Fort Worth, TX | $3.11 | 1 |
| , M.D | Family Medicine | Arlington, TX | $2.57 | 1 |
| , MD | Internal Medicine | Olney, MD | $2.54 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $3.5M
- Merck Sharp & Dohme LLC $110,825
Product Information
- Type Biological
- Total Payments $3.6M
- Total Doctors 13,214
- Transactions 23,782
About ZOSTAVAX
ZOSTAVAX is a biological associated with $3.6M in payments to 13,214 healthcare providers, recorded across 23,782 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2024. In 2024, $5,000 was paid across 1 transactions to 0 doctors.
The most common payment nature for ZOSTAVAX is "Unspecified" ($3.0M, 82.6% of total).
ZOSTAVAX is associated with 19 research studies, including "Post-licensure Evaluation of the Long-Term Effectiveness of Zostavax" ($644,477).